Stoke Therapeutics (STOK) Deferred Taxes (2018 - 2019)
Stoke Therapeutics' (STOK) quarterly Deferred Taxes came in at $6000.0 in Q4 2019, up 185.71% year-on-year from $2100.0 in Q4 2018, and down 25.0% quarter-over-quarter from $8000.0 in Q3 2019.
Stoke Therapeutics (STOK) Deferred Taxes (2018 - 2019) Analysis & Trends
Stoke Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $6000.0 for Q4 2019.
- On a quarterly basis, Deferred Taxes rose 185.71% year-over-year to $6000.0 in Q4 2019; TTM through Dec 2019 was $28000.0, a N/A change from a year earlier, with the FY2019 full-year figure at $28000.0, up 380.0% from the prior year.
- Deferred Taxes retreated to $6000.0 in Q4 2019 per STOK's latest filing, from $8000.0 in the prior quarter.
- Across five years, Deferred Taxes topped out at $8000.0 in Q3 2019 and bottomed at -$7000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 6,000.00 |
| Sep 30, 2019 | 8,000.00 |
| Jun 30, 2019 | 7,000.00 |
| Mar 31, 2019 | 7,000.00 |
| Dec 31, 2018 | -7,000.00 |
| Sep 30, 2018 | -1,000.00 |